LevelJump Announces Q2 2024 Financial Results
LevelJump Healthcare Corp (TSXV: JUMP) reported its Q2 2024 financial results, showing significant growth. Key highlights include:
- Canadian Teleradiology Services (CTS) revenues reached $4.4 million, a 42% year-over-year increase.
- Consolidated net income was $179,316 for Q2, with a year-to-date net loss of $(322,039).
- Q2 EBITDA was $655,484, with year-to-date EBITDA of $757,344.
CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues, with expectations to grow to over $20 million as the Yonge Sheppard location opens. Gross margins are projected to reach 20% or more.
LevelJump Healthcare Corp (TSXV: JUMP) ha riportato i risultati finanziari del secondo trimestre 2024, mostrando una crescita significativa. I punti salienti includono:
- I ricavi dei Servizi di Teleradiologia Canadese (CTS) hanno raggiunto 4,4 milioni di dollari, con un aumento del 42% rispetto all'anno precedente.
- L'utile netto consolidato è stato di 179.316 dollari per il secondo trimestre, con una perdita netta cumulativa di $(322.039).
- L'EBITDA del secondo trimestre è stato di 655.484 dollari, con un EBITDA cumulativo di 757.344 dollari.
Il CEO Mitch Geisler ha osservato che l'azienda sta monitorando oltre 16 milioni di dollari di ricavi annuali, con aspettative di crescita a oltre 20 milioni di dollari con l'apertura della sede di Yonge Sheppard. I margini lordi sono previsti raggiungere il 20% o più.
LevelJump Healthcare Corp (TSXV: JUMP) informó sus resultados financieros del segundo trimestre de 2024, mostrando un crecimiento significativo. Los aspectos más destacados incluyen:
- Los ingresos de Servicios de Teleradiología Canadiense (CTS) alcanzaron 4.4 millones de dólares, un incremento del 42% interanual.
- La utilidad neta consolidada fue de 179,316 dólares para el segundo trimestre, con una pérdida neta acumulada de $(322,039).
- El EBITDA del segundo trimestre fue de 655,484 dólares, con un EBITDA acumulado de 757,344 dólares.
El CEO Mitch Geisler señaló que la empresa está registrando más de 16 millones de dólares en ingresos anuales, con expectativas de crecer a más de 20 millones a medida que se abra la sede de Yonge Sheppard. Se proyecta que los márgenes brutos alcancen el 20% o más.
레벨점프 헬스케어 주식회사 (TSXV: JUMP)는 2024년 2분기 재무 실적을 보고하며 눈에 띄는 성장을 보여주었습니다. 주요 하이라이트는 다음과 같습니다:
- 캐나다 원격의료 서비스 (CTS)의 수익이 440만 달러에 달하며, 전년 동기 대비 42% 증가했습니다.
- 2분기 연결 순이익은 179,316 달러이며, 연초 대비 순손실은 $(322,039)입니다.
- 2분기 EBITDA는 655,484 달러였고, 연초 대비 EBITDA는 757,344 달러입니다.
CEO 미치 가이스러는 회사가 이제 연간 1,600만 달러 이상의 수익을 추적하고 있으며, Yonge Sheppard 지점 개설에 따라 2,000만 달러를 넘길 것으로 예상하고 있다고 언급했습니다. 총 이익률은 20% 이상 도달할 것으로 예상됩니다.
LevelJump Healthcare Corp (TSXV: JUMP) a annoncé ses résultats financiers pour le deuxième trimestre 2024, montrant une croissance significative. Les points forts incluent :
- Les revenus des Services de Téléradiologie Canadienne (CTS) ont atteint 4,4 millions de dollars, soit une augmentation de 42 % par rapport à l'année précédente.
- Le bénéfice net consolidé s'est élevé à 179.316 dollars pour le deuxième trimestre, avec une perte nette cumulée de $(322.039).
- L'EBITDA du deuxième trimestre était de 655.484 dollars, avec un EBITDA cumulé de 757.344 dollars.
Le PDG Mitch Geisler a noté que l'entreprise suit maintenant plus de 16 millions de dollars de revenus annuels, avec des attentes de croissance à plus de 20 millions de dollars avec l'ouverture de l'emplacement Yonge Sheppard. Les marges brutes devraient atteindre 20 % ou plus.
LevelJump Healthcare Corp (TSXV: JUMP) hat die finanziellen Ergebnisse des zweiten Quartals 2024 veröffentlicht und ein signifikantes Wachstum gezeigt. Wichtige Highlights sind:
- Die Einnahmen der Kanadischen Teleradiologie Dienste (CTS) beliefen sich auf 4,4 Millionen Dollar, was einem Anstieg von 42% im Vergleich zum Vorjahr entspricht.
- Der konsolidierte Nettogewinn betrug 179.316 Dollar für das zweite Quartal, mit einem kumulierten Nettverlust von $(322.039).
- Das EBITDA im zweiten Quartal lag bei 655.484 Dollar, mit einem kumulierten EBITDA von 757.344 Dollar.
CEO Mitch Geisler merkte an, dass das Unternehmen jetzt über 16 Millionen Dollar an jährlichen Einnahmen verfolgt und erwartet, mit der Eröffnung des Standorts Yonge Sheppard auf über 20 Millionen Dollar zu wachsen. Die Bruttomargen werden voraussichtlich 20% oder mehr erreichen.
- CTS revenues increased by 42% year-over-year in Q2
- Q2 consolidated net income of $179,316
- Q2 EBITDA of $655,484
- Company tracking over $16 million in annual revenues
- Projected revenue growth to over $20 million with new location opening
- Year-to-date net loss of $(322,039)
Toronto, Ontario--(Newsfile Corp. - August 30, 2024) - LevelJump Healthcare Corp (TSXV: JUMP) ("LevelJump" or the "Company"), announced today its reported financial results for the quarter ended June 30, 2024.
Financial and Operational Highlights
- Revenues from Canadian Teleradiology Services, Inc. ("CTS") were
$4.4 million for the second quarter.
- Gross profit from CTS operations was
$911,000 for the quarter.
- CTS Year over year second quarter revenues increased by
42% .
2024 Q2 Financial Results for LevelJump
- Consolidated net income in the second quarter of 2024 was
$179,316 , year to date net loss of$(322,039) .
- Consolidated EBITDA in the second quarter of 2024 was
$655,484 , year to date EBITDA of$757,344.
Management Comments
"The second quarter was quite strong, and we are now tracking over
Non-IFRS Financial Measures
This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.
Adjusted EBITDA & Annual Revenue Run Rate
Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.
EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment and finance income.
A reconciliation of adjusted EBITDA to net income (loss) is as follows:
| Three Months ended June 30 | Six Months ended June 30 | |||||||||||||||
| ($ in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net and comprehensive income (loss) | 179 | (237) | (322) | (445) | ||||||||||||
| Add back: | ||||||||||||||||
| Depreciation and amortization | 318 | 120 | 628 | 212 | ||||||||||||
| Net interest expense | 271 | 61 | 507 | 117 | ||||||||||||
| Stock-based compensation | - | - | - | - | ||||||||||||
| Taxes | - | - | - | 9 | ||||||||||||
| Misc and foreign exchange | (113 | ) | (114 | ) | (55 | ) | (116 | ) | ||||||||
| EBITDA | 655 | (170 | ) | 757 | (223 | ) | ||||||||||
| Add back: | ||||||||||||||||
| Broker commissions for financing | - | 67 | - | 67 | ||||||||||||
| One-time Professional Fees related to Acquisitions | - | 20 | - | 100 | ||||||||||||
| Adjusted EBITDA | 655 | (83 | ) | 757 | (56 | ) | ||||||||||
For further details on the results, please refer to Leveljump's Management, Discussion and Analysis and Consolidated Financial Statements for the Three Months and Six Months Ended June 30, 2024, which are available on the Company's website (www.leveljumphealthcare.com) and under the Company's profile on SEDAR (www.sedarplus.ca).
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler
Chief Executive Officer
info@leveljumphealthcare.com
647-340-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221618
FAQ
What was LevelJump Healthcare's (TSXV: JUMP) revenue for Q2 2024?
How much did LevelJump's (TSXV: JUMP) CTS revenues grow year-over-year in Q2 2024?
What was LevelJump Healthcare's (TSXV: JUMP) EBITDA for Q2 2024?
What is LevelJump Healthcare's (TSXV: JUMP) projected annual revenue?
